New Genetic Targets Identified Treat Chemo-resistant Breast Cancer

In treating triple negative breast cancer, two new potential targets MCL1 and MYC genes have been identified, which are linked with chemotherapy resistance.

Two new potential targets for treating triple negative breast cancer, which is the most triple negative breast cancer have been identified, reveals a new study.

The research was led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center.

Role of Testosterone in Triple Negative Breast Cancer Examined in Mayo Clinic-TGen Study
There is hope that blocking a testosterone receptor might lead to a new way to treat an aggressive form of breast cancer.

‘Drugs that inhibit the activity of MCL1 or MYC genes are being developed and combining these with the standard chemotherapy can slow or even prevent the development of chemotherapy resistance.’

Increased activity of two genes, MCL1 and MYC, is associated with the development of chemotherapy resistance. The increased action of these two genes boosts mitochondrial oxidative phosphorylation, which promotes the growth of chemotherapy-resistant cancer stem cells, the research showed.

"Alterations in these two genes are easily detectable with tumor gene tests in current use. Combinations of drugs that inhibit MCL1 or MYC, or both, have the potential to reduce the development of chemotherapy resistance and should be studied in clinical trials," said Dr. Arteaga, Professor of Internal Medicine at UT Southwestern Medical Center. Dr. Arteaga holds The Lisa K. Simmons Distinguished Chair in Comprehensive Oncology.

Most breast cancers can be treated with hormone therapy, but about 15 percent of cases are triple negative breast cancer, meaning the cancer cells are not influenced by hormones like estrogen or progesterone.

Two New Drug Targets for Triple Negative Breast Cancer
The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment.

These triple negative breast cancers must, therefore, be treated with chemotherapy, which is toxic to healthy cells as well as cancer cells.

Furthermore, most triple negative breast cancers eventually become resistant to chemotherapy and the cancer then spreads unchecked.

Triple Negative Breast Cancer Varies Between African-American and European-American Women
Triple Negative Breast Cancer is a highly aggressive breast cancer subtype that afflicts African-American women at a higher rate than white women, and often involves a worse prognosis

Drugs that inhibit activity of the MCL1 or MYC genes are in development, Dr. Arteaga said. These drugs, given in conjunction with standard chemotherapies, could potentially slow or even prevent the development of chemotherapy resistance, improving the outlook for this aggressive form of breast cancer.

Chemo-resistance in Triple Negative Breast Cancer Linked To Mesenchymal Stem Cells In Tumor
Adipose tissue derived mesenchymal stem cells could contribute to chemoresistance in triple negative breast cancer (TNBC).

Source-Eurekalert